These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16792841)

  • 1. Effects of metformin on inappropriate LH release in women with polycystic ovarian syndrome and insulin resistance.
    Ulloa-Aguirre A; Portocarrero L; Zariñán T; Olivares A; Carranza-Lira S; Veldhuis JD; López-Alvarenga JC
    Reprod Biomed Online; 2006 Jun; 12(6):669-83. PubMed ID: 16792841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome.
    Unlühizarci K; Keleştimur F; Bayram F; Sahin Y; Tutuş A
    Clin Endocrinol (Oxf); 1999 Aug; 51(2):231-6. PubMed ID: 10468995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of GnRH-stimulated LH release to episodic LH secretion and baseline endocrine-metabolic measures in women with polycystic ovary syndrome.
    Patel K; Coffler MS; Dahan MH; Malcom PJ; Deutsch R; Chang RJ
    Clin Endocrinol (Oxf); 2004 Jan; 60(1):67-74. PubMed ID: 14678290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of metformin treatment on luteal phase progesterone concentration in polycystic ovary syndrome.
    Meenakumari KJ; Agarwal S; Krishna A; Pandey LK
    Braz J Med Biol Res; 2004 Nov; 37(11):1637-44. PubMed ID: 15517078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of metformin on serum insulin and anti-Mullerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome.
    Nascimento AD; Silva Lara LA; Japur de Sá Rosa-e-Silva AC; Ferriani RA; Reis RM
    Gynecol Endocrinol; 2013 Mar; 29(3):246-9. PubMed ID: 23194004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of hyperinsulinemia in pathogenesis of polycystic ovary syndrome and treatment by reduction of insulin secretion].
    Wang A; Li M; Lu C
    Zhonghua Fu Chan Ke Za Zhi; 1998 Dec; 33(12):731-4. PubMed ID: 10806662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obese patients with polycystic ovary syndrome: evidence that metformin does not restore sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by ovarian steroids.
    Eagleson CA; Bellows AB; Hu K; Gingrich MB; Marshall JC
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5158-62. PubMed ID: 14602743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.
    Morales AJ; Laughlin GA; Bützow T; Maheshwari H; Baumann G; Yen SS
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2854-64. PubMed ID: 8768842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of metformin on the plasminogen activator system, endocrine, metabolic profiles in patients with polycystic ovary syndrome and clomiphene resistant cases].
    Song J; Shen H; Li J; Huang Z; Zhang Y
    Zhonghua Fu Chan Ke Za Zhi; 2002 Feb; 37(2):86-9. PubMed ID: 11953071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome.
    Genazzani AD; Battaglia C; Malavasi B; Strucchi C; Tortolani F; Gamba O
    Fertil Steril; 2004 Jan; 81(1):114-9. PubMed ID: 14711553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
    Genazzani AD; Lanzoni C; Ricchieri F; Baraldi E; Casarosa E; Jasonni VM
    Gynecol Endocrinol; 2007 Mar; 23(3):146-52. PubMed ID: 17454168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
    Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.
    Ganie MA; Khurana ML; Nisar S; Shah PA; Shah ZA; Kulshrestha B; Gupta N; Zargar MA; Wani TA; Mudasir S; Mir FA; Taing S
    J Clin Endocrinol Metab; 2013 Sep; 98(9):3599-607. PubMed ID: 23846820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are circulating leptin and luteinizing hormone synchronized in patients with polycystic ovary syndrome?
    Sir-Petermann T; Piwonka V; Pérez F; Maliqueo M; Recabarren SE; Wildt L
    Hum Reprod; 1999 Jun; 14(6):1435-9. PubMed ID: 10357954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The utility of the gonadotrophin releasing hormone (GnRH) test in the diagnosis of polycystic ovary syndrome (PCOS).
    Lewandowski KC; Cajdler-Łuba A; Salata I; Bieńkiewicz M; Lewiński A
    Endokrynol Pol; 2011; 62(2):120-8. PubMed ID: 21528473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of hypothalamic-pituitary-gonadal disruption in polycystic ovarian syndrome.
    Barontini M; García-Rudaz MC; Veldhuis JD
    Arch Med Res; 2001; 32(6):544-52. PubMed ID: 11750729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Endocrine and metabolic effects of metformin in combination with compound cyproterone acetate in women with polycystic ovarian syndrome].
    Ye BL; Yang HY; Zhao JZ; Lin JJ; Lin WQ
    Zhonghua Fu Chan Ke Za Zhi; 2003 Dec; 38(12):745-8. PubMed ID: 14728846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
    Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
    Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased luteinizing hormone secretion in women with polycystic ovary syndrome is unaltered by prolonged insulin infusion.
    Patel K; Coffler MS; Dahan MH; Yoo RY; Lawson MA; Malcom PJ; Chang RJ
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5456-61. PubMed ID: 14602789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study.
    Pau CT; Keefe C; Duran J; Welt CK
    J Clin Endocrinol Metab; 2014 May; 99(5):1870-8. PubMed ID: 24606093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.